Literature DB >> 22905639

Shifting sands: changing regional and gender-specific patterns of HIV/AIDS mortality in Canada, 1987 to 2008.

Lindsay M Belvedere1, Caroline L Miller, Robert S Hogg.   

Abstract

OBJECTIVE: To assess patterns of HIV-related mortality by period, gender and age group in Canada from 1987 to 2008.
METHODS: We applied standard demographic techniques to assess changes in HIV/AIDS mortality over five time periods: 1987-1991, 1992-1996, 1997-2001, 2002-2006, and 2007-2008. HIV/AIDS-related mortality was based on deaths in which HIV infection or AIDS was reported as the underlying cause of death. Population figures were obtained from annual estimates. Age-, sex- and province-specific crude and standardized HIV/AIDS mortality rates and ratios were used to examine changes in mortality.
RESULTS: In the period from 1987 to 2008, there were 17,287 HIV/AIDS-related deaths; of these, 15,587 (90.2%) occurred among men and 1,700 (9.8%) among women. Standardized and age-specific death rates were generally higher in men than women. Among men, rates of mortality were highest in Quebec and British Columbia; and among women, rates increased over time in British Columbia and the Prairies and decreased in Quebec. In general, rates of death were highest in 1992-1996 and lowest in the latest period.
CONCLUSION: We observed a sharp decline in mortality rates with the introduction of HAART; however, the rates were higher among men in Quebec and British Columbia and among women in British Columbia, Quebec and the Prairies.

Entities:  

Mesh:

Year:  2012        PMID: 22905639      PMCID: PMC6974229     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  13 in total

1.  Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.

Authors:  Nancy F Crum; Robert H Riffenburgh; Scott Wegner; Brian K Agan; Sybil A Tasker; Katherine M Spooner; Adam W Armstrong; Susan Fraser; Mark R Wallace
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

2.  Estimates of HIV prevalence and incidence in Canada, 2005.

Authors:  D Boulos; P Yan; D Schanzer; R S Remis; C P Archibald
Journal:  Can Commun Dis Rep       Date:  2006-08-01

3.  Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States.

Authors:  Kathleen McDavid Harrison; Ruiguang Song; Xinjian Zhang
Journal:  J Acquir Immune Defic Syndr       Date:  2010-01       Impact factor: 3.731

4.  Social and structural determinants of HAART access and adherence among injection drug users.

Authors:  Andrea Krüsi; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  Int J Drug Policy       Date:  2009-09-10

5.  Cohort profile: the Canadian Observational Cohort collaboration.

Authors:  Alexis K Palmer; Marina B Klein; Janet Raboud; Curtis Cooper; Sean Hosein; Mona Loutfy; Nima Machouf; Julio Montaner; Sean B Rourke; Marek Smieja; Christos Tsoukas; Benita Yip; David Milan; Robert S Hogg
Journal:  Int J Epidemiol       Date:  2010-02-15       Impact factor: 7.196

6.  Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations.

Authors:  C L Miller; P M Spittal; E Wood; K Chan; M T Schechter; J S G Montaner; R S Hogg
Journal:  AIDS Care       Date:  2006-11

7.  Seroprevalence and correlates of HIV and HCV among injecting drug users in Edmonton, Alberta.

Authors:  Sabrina S Plitt; Jennifer Gratrix; Sharyn Hewitt; Patsy Conroy; Tracy Parnell; Beverly Lucki; Vicki Pilling; Barbara Anderson; Yogesh Choudri; Chris P Archibald; Ameeta E Singh
Journal:  Can J Public Health       Date:  2010 Jan-Feb

8.  Morbidity and mortality related to human immunodeficiency virus in Canadian men and women, 1987-94.

Authors:  A E Weber; R S Hogg
Journal:  Can J Public Health       Date:  1999 Mar-Apr

9.  Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment program.

Authors:  Christopher G Au-Yeung; Aranka Anema; Keith Chan; Benita Yip; Julio S G Montaner; Robert S Hogg
Journal:  BMC Public Health       Date:  2010-10-25       Impact factor: 3.295

10.  HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials.

Authors:  R S Hogg; K V Heath; S A Strathdee; J S Montaner; M V O'Shaughnessy; M T Schechter
Journal:  AIDS       Date:  1996-07       Impact factor: 4.177

View more
  4 in total

1.  Reductions in all-cause and cause-specific mortality among HIV-infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001-2012.

Authors:  C C Cheung; E Ding; P Sereda; B Yip; L Lourenco; R Barrios; Jsg Montaner; R S Hogg; V Lima; D M Moore
Journal:  HIV Med       Date:  2016-06-09       Impact factor: 3.180

2.  Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.

Authors:  Sophie Patterson; Angela Cescon; Hasina Samji; Keith Chan; Wendy Zhang; Janet Raboud; Ann N Burchell; Curtis Cooper; Marina B Klein; Sean B Rourke; Mona R Loutfy; Nima Machouf; Julio S G Montaner; Chris Tsoukas; Robert S Hogg
Journal:  BMC Infect Dis       Date:  2015-07-17       Impact factor: 3.090

3.  Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study.

Authors:  Angela Cescon; Sophie Patterson; Keith Chan; Alexis K Palmer; Shari Margolese; Ann N Burchell; Curtis Cooper; Marina B Klein; Nima Machouf; Julio S G Montaner; Chris Tsoukas; Robert S Hogg; Janet M Raboud; Mona R Loutfy
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

4.  Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012.

Authors:  Oghenowede Eyawo; Conrado Franco-Villalobos; Mark W Hull; Adriana Nohpal; Hasina Samji; Paul Sereda; Viviane D Lima; Jeannie Shoveller; David Moore; Julio S G Montaner; Robert S Hogg
Journal:  BMC Infect Dis       Date:  2017-02-27       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.